AHNAK promotes oxidative stress and inflammatory responses in chronic obstructive pulmonary disease by activating the Notch pathway Authors: Chunhui Zhang, Yu Liu Published: 2026 ABSTRACT Chronic obstructive pulmonary disease (COPD) is a common respiratory disease with high mortality. AHNAK nucleoprotein (AHNAK) is predicted to be highly expressed in COPD; however, its role remains unclear. This study aimed to investigate the role of AHNAK in COPD and the underlying molecular mechanism. A549 cells were treated with cigarette smoke extract (CSE) as an in vitro model, while a COPD mouse model was established using cigarette smoke (CS) exposure and lipopolysaccharide (LPS) on the C57BL/6J mice. Oxidative stress and inflammation were evaluated in cells and serum of mice. The regulation of ANHAK on the Notch pathway was evaluated using Western blot. The results showed that AHNAK was highly expressed in the serum of patients with COPD and CSE-induced A549 cells. Knockdown of AHNAK inhibited oxidative stress and inflammatory responses both in vitro and in vivo, and alleviated lung injury in COPD mice. Additionally, AHNAK knockdown suppressed the activation of the Notch pathway in CSE-induced cells, and activating this pathway reversed the inhibition of oxidative stress and inflammation caused by AHNAK silence. In conclusion, silencing of AHNAK decelerates the progression of COPD by inhibiting oxidative stress and inflammation via the inactivation of the Notch pathway. The findings suggest that targeting AHNAK may be a promising therapeutic strategy for COPD. Introduction Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, with over 3 million deaths each year, making it a significant health concern (1,2). Its global prevalence is particularly high, affecting approximately 10% of individuals (3). In addition to genetic factors, smoking is a significant contributor to COPD, and other factors such as environmental pollution, occupational exposure, and asthma also serve as risk factors for COPD (4,5). Diagnosis typically relies on spirometry, which measures airflow obstruction, and is often delayed due to extremely mild symptoms in the early stage (6). Current treatment strategies include smoking cessation, bronchodilators, corticosteroids, and pulmonary rehabilitation. However, these interventions only manage symptoms and slow disease progression, rather than providing a cure (7,8). Thus, the prognosis of COPD is very poor. Moreover, the poor prognosis is also influenced by various comorbidities caused by COPD, such as cardiovascular diseases, osteoporosis, and cancer (9,10). Understanding the molecular mechanisms influencing the progression of COPD is crucial for developing more effective therapies to improve prognosis. AHNAK nucleoprotein (AHNAK) is a 700-kDa giant scaffolding protein that regulates various biological processes, involving the formation of the blood-brain barrier, cell structure and movement, calcium signal integration, membrane repair, and tumor metastasis (11). Increasing studies have begun to explore the regulatory role of AHNAK in pathological physiological processes in diseases. It has been reported that AHNAK affects the progression of several diseases, such as cancer, lung fibrosis, and skin disease (12-14). The results of a bioinformatics analysis and a genome-wide linkage study have indicated that AHNAK was highly expressed in the serum of patients with COPD and was helpful for the diagnosis (15,16). Moreover, AHNAK is identified to be closely related to immune infiltration in the progression of COPD (17). However, how AHNAK affects the progression of COPD has not yet been fully clarified. In the present study, we investigated the functional role of AHNAK in COPD and the underlying molecular mechanism. This study reveals the possibility that AHNAK may become a therapeutic target for COPD by uncovering the signals driven by AHNAK, in order to slow down disease progression and improve the poor prognosis. We present this article in accordance with the ARRIVE and MDAR reporting checklists (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-aw-2275/rc). Methods Identification of differentially expressed genes (DEGs) RNA sequencing data were acquired from the Gene Expression Omnibus (GEO) database (GSE57148 dataset). This dataset detected RNA expression in the lung tissues of 98 patients with COPD and 91 participants with normal spirometry. For inclusion, the participants in the COPD group had a postbronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio below 0.7, and those in the control group showed normal spirometry according to the American Thoracic Society/European Respiratory Society criteria (18). Data were analyzed using the R language “LIMMA” package. DEGs were screened following the criteria: |log2 (fold change)| >0.3 and adjusted P value <0.05. The results were visualized using the volcano plots with the R “EnhancedVolcano” package. AHNAK-correlated genes were predicted using the Pearson correlation coefficient. A correlation value greater than 0.3 or less than −0.3 was considered to have a positive or negative correlation. A pathway enrichment analysis was carried out on AHNAK-related genes using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Clinical sample collection Serum samples were collected from 36 patients with COPD and 36 healthy participants. COPD was diagnosed according to the Global Initiative for COPD. Normal individuals had normal pulmonary function without a COPD history. Patients with other respiratory system diseases, lung cancer, autoimmune diseases, cardiopulmonary insufficiency, and pregnant women were excluded. Blood samples were collected from all participants, and serum was obtained after centrifuging at 3,000 rpm for 10 min. This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The study was approved by the Ethics Committee of Fujian Provincial Geriatric Hospital. Informed consent was obtained from all individual participants included in the study. Cell culture Human lung epithelial cells (A549; RRID: CVCL_0023) were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1% penicillin-streptomycin (Gibco) in a humidity incubator with 5% CO2 at 37 ℃. CSE was prepared as previously described (19). CSE was diluted to a concentration of 10% with serum-free DMEM. To establish an in vitro model, A549 cells were treated with 10% CSE for 24 h at 37 ℃. Valproic acid (VPA), a Notch pathway agonist, was purchased from MedChemExpress (Monmouth Junction, NJ, USA). A549 cells were treated with 4 mM VPA for 24 h to activate the Notch pathway. Cell transfection A549 cells were seeded in six-well plates one day before transfection. The cells were transfected with AHNAK short hairpin RNA (shAHNAK, target sequences: GCAGCTCTGAAGTGGTTCTGA) and the negative control (shNC, CAACAAGATGAAGGCACCAA) plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Forty-eight hours later, the cells were harvested. Quantitative real-time polymerase chain reaction (qPCR) Total RNA was extracted from human serum and A549 cells using TRIzol reagent (Invitrogen). After detecting RNA concentration using the Nanodrop Eight system (Thermo Scientific, Waltham, MA, USA), reverse transcription was detected using the high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). qPCR was performed using the PowerUp SYBR Green Master Mix (Applied Biosystems). Gene expression was calculated using the 2−ΔΔCT method. Cell Counting Kit-8 (CCK-8) A549 cells were seeded in 96-well plates at a density of 2×103 cells per well. After incubation for 24 h, the cells were incubated with 10 µL of CCK-8 reagent (Sigma-Aldrich, St. Louis, MO, USA) for 2 h at 37 ℃. The absorbance was measured at 450 nm using a microplate reader. Detection of superoxide dismutase (SOD) activity, malondialdehyde (MDA) content, and lactate dehydrogenase (LDH) activity A549 cells (5×106 cells) were mixed with 1 mL of the extracting solution and disrupted by ultrasound. After centrifuging at 8,000 g for 10 min, the supernatant was collected for use. Serum of mice was directly used for detection. Lung tissues of mice and the extracting solution were mixed in a ratio of 1:10. Then, they were homogenized on ice and centrifuged at 8,000 g for 10 min. The supernatant was collected. SOD activity was measured using the SOD activity assay kit (Solarbio, Beijing, China). The samples (20 µL) were incubated with 45 µL of reagent 1, 20 µL of reagent 2, 35 µL of reagent 3, 70 µL of distilled water, and 10 µL of reagent 4 at 37 ℃ for 30 min. The absorbance was detected at 450 nm using a microplate reader. MDA contents were detected using the MDA content assay kit (Solarbio). The samples (200 µL) were incubated with 400 µL of reagent 1, 200 µL of reagent 2, 100 µL of reagent 3, and 100 µL of reagent 4 in a water bath at 100 ℃ for 60 min. After centrifuging at 13,500 rpm for 10 min. The supernatant was obtained, and the absorbance was detected at 532 and 600 nm. The LDH activity assay kit (Solarbio) was used to measure LDH activity. The samples (50 µL) were incubated with 250 µL of reagent 1 and 50 µL of reagent 2 at 37 ℃ for 15 min. The reaction solution was further incubated with 250 µL of reagent 3 at 37 ℃ for 15 min. After mixing with 750 µL of reagent 4, the absorbance value was detected at 450 nm. Determination of ROS levels ROS fluorescent probe-dihydroethidium (DHE) was purchased from Vigorous Biotechnology (Beijing, China). The probe was dissolved in fresh culture medium. A549 cells were incubated with 5 µM probe solution at 37 ℃ for 60 min in the dark. After washing with phosphate-buffered saline (PBS), the cells were observed under a fluorescence microscope. Enzyme-linked immunosorbent assay (ELISA) Cell culture medium was collected and centrifuged at 3,000 rpm for 20 min, and the supernatant was collected. The levels of tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-6 were detected using the human TNF-α ELISA kit and the human IL-6 ELISA kit (COIBO Bio, Shanghai, China) following the manufacturer’s instructions. The levels of TNF-α and IL-6 in the serum of mice were measured using the mouse ELISA kits (COIBO Bio). Western blot A549 cells were lysed using Radio Immunoprecipitation Assay (RIPA) buffer (Beyotime, Shanghai, China) with 1 mM phenylmethanesulfonyl fluoride (PMSF; Beyotime). The protein concentration in the lysate was detected using an enhanced bicinchoninic acid (BCA) protein assay kit (Beyotime). Afterward, proteins were separated using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride membranes. After blocking the membranes using 5% skim milk for 1 h, the membranes were incubated at 4 ℃ overnight with primary antibodies, including Notch1 (20687-1-AP; Proteintech, Wuhan, China), Notch4 (33280-1-AP; Proteintech), Hes1 (ab71559; Abcam, Cambridge, MA, USA), Hey1 (19929-1-AP; Proteintech), and β-actin (20536-1-AP; Proteintech). The membranes were washed with Tris Buffered Saline with Tween 20 (TBST) and incubated at room temperature for 1 h with horseradish peroxidase conjugated goat anti-rabbit immunoglobulin G (IgG; ab205718; Abcam). Following washing with TBST, the protein bands were visualized using BeyoECL Plus (Beyotime) and imaged. Establishment of the COPD mouse model and adeno-associated virus (AAV) injection C57BL/6J mice (male, 8-week-old, weight 21–24 g) were purchased from Cavens (Changzhou, China). The mice were housed in specific pathogen free (SPF) environment with a temperature of 22±2 ℃, 50–60% humidity, and 12-hour light and dark cycles. A total of 24 mice were randomly divided into four groups: control, COPD, COPD + shNC, and COPD + shAHNAK (n=6 per group). Randomization was performed using the web-based software Randomizer. A COPD mouse model was established using CS exposure and LPS injection as previously described (20). Briefly, the mice were given four cigarettes each day, five days a week, during the first week. The mice were then exposed to smoke from six cigarettes each day, 5 days a week, from the second week to the sixth week. Besides, at the end of the third and fifth weeks, mice received an intratracheal injection of either 750 ng/kg LPS (Sigma-Aldrich) solution (LPS was dissolved in 50 µL of normal saline). The mice in the control group were injected intratracheally with 50 µL of normal saline without smoke exposure. To explore the role of AHNAK, shNC and shAHNAK were delivered using AAV. One week before model generation, AAV-shNC and AAV-shAHNAK (1×1011 vg/mouse) were intratracheally injected into mice. At the end of the 7th week, all mice were euthanized by inhaling 5% isoflurane (Sigma-Aldrich). The blood and lungs of mice were collected. The serum was acquired from the blood by centrifuging at 3,000 rpm for 10 min. The lungs were fixed with 4% paraformaldehyde for 24 h for use. The authors have confirmed that all animal procedures were performed in accordance with the relevant guidelines for the care and humane use of laboratory animals. Hematoxylin and eosin (H&E) staining The lung tissues were embedded in paraffin and cut into 5 µm-thick sections. The H&E stain kit (Solarbio) was used for histopathological analysis. Then, the sections were dewaxed to water, stained with hematoxylin staining solution for 5 min, followed by staining with eosin for 1 min. After dehydration, transparency, and sealing, the sections were observed under a light microscope. The analysis of all histological sections was conducted in a blinded manner. Mean linear intercept (MLI) was quantified to assess emphysema according to previously described (21). Briefly, lines for cross-referencing were created in the middle of each microscopic field. The total length (L) and the number of alveolar septa (NS) were measured. The MLI was calculated using the formula: L/NS. Statistical analysis In vitro experiments included three biological repetitions and three technical repetitions. In vivo experiments were performed using six mice per group. Data were analyzed using the GraphPad Prism 8 software, and the results are displayed as means ± standard deviation (SD). Multiple comparisons were performed using one-way analysis of variance (ANOVA), while t-test was used to compare the difference between two groups. A receiver operating characteristic (ROC) curve was drawn to evaluate the diagnostic performance, and the area under the curve (AUC) was calculated. P<0.05 indicates statistical significance. Results AHNAK is highly expressed in patients with COPD and CSE-treated A549 cells To identify genes that can influence the progression of COPD, DEGs were predicted using the GSE57148 dataset. We screened 575 downregulated genes and 519 upregulated genes in patients with COPD (Figure 1A). Then, we collected blood samples from patients with COPD and normal individuals. The expression of AHNAK was detected in these samples. The results showed that AHNAK expression was higher in patients with COPD than that in normal participants (Figure 1B). The analysis of the ROC curves showed that the AUC value was 0.9171 (P<0.001; Figure 1C), suggesting the diagnostic performance of AHNAK for COPD. Additionally, A549 cells were stimulated with CSE to establish an in vitro model, and AHNAK expression was detected using qPCR. As shown in Figure 1D, AHNAK expression was increased in CSE-treated cells, compared with the control group. The results suggest that AHNAK may be involved in COPD progression. AHNAK is highly expressed in patients with COPD and CSE-treated A549 cells. (A) Volcano plots showed DEGs between patients with COPD and participants with normal spirometry from the GSE57148 dataset. (B) AHNAK expression in the blood of patients with COPD and normal participants was detected using qPCR (n=36). (C) ROC curves for AHNAK. (D) AHNAK expression in CSE-treated A549 cells and the control group (normal A549 cells) was detected using qPCR (n=3). P<0.001 indicates statistical significance. AHNAK, AHNAK nucleoprotein; AUC, area under the curve; COPD, chronic obstructive pulmonary disease; CSE, cigarette smoke extract; DEGs, differentially expressed genes; FC, fold change; qPCR, quantitative real-time polymerase chain reaction; ROC, receiver operating characteristic. Knockdown of AHNAK inhibits oxidative stress and inflammatory responses To investigate the effect of AHNAK on cellular biological functions, A549 cells were transfected with shAHNAK and shNC. We found that AHNAK expression was lower in the shAHNAK group than that in the shNC group (Figure 2A). CSE treatment induced the enhancement of cell viability, and AHNAK knockdown reduced the viability of CSE-induced cells (Figure 2B). SOD activity was reduced in CSE-stimulated cells, while silencing of AHNAK reversed this reduction induced by CSE (Figure 2C). Inversely, CSE increased MDA contents and LDH activity, whereas knockdown of AHNAK reduced MDA contents and LDH activity in CSE-induced A549 cells (Figure 2D,2E). The levels of TNF-α and IL-6 were elevated by CSE treatment, and AHNAK knockdown decreased their levels in CSE-induced cells (Figure 2F,2G). Furthermore, ROS levels were measured using the DHE probe. The results showed that CSE treatment increased ROS levels, which was rescued by AHNAK silence (Figure 2H). Together, CSE promotes oxidative stress and inflammatory responses of A549 cells, and silencing of AHNAK inhibits these functions of CSE-induced cells. Knockdown of AHNAK inhibits oxidative stress and inflammatory responses. (A) AHNAK expression was detected in A549 cells following shNC and shAHNAK transfection. (B) Cell viability was detected using CCK-8. (C) SOD activity, (D) MDA contents, and (E) LDH activity were measured using their corresponding commercialized kits. (F) TNF-α and (G) IL-6 levels were measured in the cell culture supernatant using ELISA kits. (H) ROS levels were measured using the DHE fluorescence probe. All n=3. P<0.001 and P<0.01 indicate statistical significance. AHNAK, AHNAK nucleoprotein; CCK-8, Cell Counting Kit-8; CSE, cigarette smoke extract; DAPI, 4’,6-diamidino-2-phenylindole; DHE, dihydroethidium; ELISA, enzyme-linked immunosorbent assay; IL, interleukin; LDH, lactate dehydrogenase; MDA, malondialdehyde; ROS, reactive oxygen species; shNC, short hairpin RNA negative control; SOD, superoxide dismutase; TNF-α, tumor necrosis factor-alpha. Knockdown of AHNAK attenuates lung injury, oxidative stress, and inflammation To investigate the role of AHNAK in vivo, a COPD mouse model was established, and AAV-shAHNAK was injected. Then, we performed H&E staining to assess pulmonary histopathology. As shown in Figure 3A,3B, the lung tissues of mice in the COPD group were dilated, the alveolar cavities were enlarged, and the alveolar walls were thinner. However, knocking down AHNAK improved these adverse changes. MLI quantification results further demonstrated that silencing of AHNAK attenuated emphysema in the COPD mouse model (Figure 3B). Next, we measured oxidative stress indicators in the lungs and serum of mice. The results showed that SOD activity was declined, while MDA contents were elevated both in the lung tissues and the serum of COPD mice; however, AHNAK silence increased SOD activity and reduced MDA contents in the mouse model (Figure 3C-3F). Additionally, LDH activity, TNF-α levels, and IL-6 levels were all elevated in the COPD group, whereas knockdown of AHNAK reversed this elevation in the mice (Figure 3G-3I). The results demonstrate that silencing of AHNAK decelerates COPD progression by inhibiting oxidative stress and inflammation. Knockdown of AHNAK attenuates lung injury, oxidative stress, and inflammation. (A) The pathology of the lung tissues of mice was evaluated using H&E staining assay. (B) Emphysema was assessed by quantification of MLI. (C) SOD activity and (D) MDA contents in the lung tissues of mice were measured by commercialized kits. (E) SOD activity, (F) MDA contents, and (G) LDH activity in the serum of mice were measured using their corresponding commercialized kits. (H) TNF-α and (I) IL-6 levels in the serum of mice were detected using ELISA. All n=6. P<0.001 indicates statistical significance. AHNAK, AHNAK nucleoprotein; CON, control; COPD, chronic obstructive pulmonary disease; ELISA, enzyme-linked immunosorbent assay; H&E, hematoxylin and eosin; IL, interleukin; LDH, lactate dehydrogenase; MDA, malondialdehyde; MLI, mean linear intercept; shNC, short hairpin RNA negative control; SOD, superoxide dismutase; TNF-α, tumor necrosis factor-alpha. Knockdown of AHNAK inhibits the activation of the Notch pathway To investigate the possible downstream signaling pathways that may be modulated by AHNAK, the AHNAK-correlated genes were predicted. Among the genes from the GSE57148 dataset, 4,061 genes were positively correlated to AHNAK, and 3,555 genes were negatively correlated to AHNAK (Figure 4A). All the correlated genes were enriched using KEGG enrichment analysis. They were enriched in several pathways, such as the Notch signaling pathway, metabolism, DNA replication, ferroptosis, and hedgehog signaling pathway (Figure 4B). Subsequently, we confirmed that AHNAK can indeed regulate the Notch pathway using Western blot. The results showed that Notch1, Notch4, Hes1, and Hey1 levels were upregulated in CSE-induced A549 cells, which was reversed after silencing of AHNAK (Figure 4C). In short, silencing of AHNAK inactivates the Notch pathway in the CSE-induced cells. Knockdown of AHNAK inhibits the activation of the Notch pathway. (A) The correlation between the genes in the GSE57148 dataset and AHNAK was predicted using the Pearson correlation coefficient. (B) KEGG enrichment analysis of all AHNAK-correlated genes. (C) Western blot was conducted to determine Notch1, Notch4, Hes1, and Hey1 protein levels in CSE-induced A549 cells with shAHNAK transfection. All n=3. AHNAK, AHNAK nucleoprotein; Cor, correlation; CSE, cigarette smoke extract; KEGG, Kyoto Encyclopedia of Genes and Genomes; shNC, short hairpin RNA negative control. Knockdown of AHNAK inhibits oxidative stress and inflammatory responses by inactivating the Notch pathway To investigate the involvement of the Notch pathway in cellular biological function, a Notch pathway agonist, VPA, was used to treat A549 cells. We found that agonist treatment suppressed cell viability after knocking down AHNAK (Figure 5A). SOD activity that was enhanced by knockdown of AHNAK was counteracted by agonist treatment (Figure 5B). MDA contents, LDH activity, as well as the levels of TNF-α and IL-6, were all decreased in CSE-induced cells after knocking down AHNAK, while agonist treatment reversed this decrease (Figure 5C-5F). Moreover, AHNAK silence reduced ROS levels, which was rescued after agonist treatment (Figure 5G). The results demonstrate that silencing of AHNAK inhibits oxidative stress and inflammatory responses of CSE-induced cells by suppressing the activation of the Notch pathway. Knockdown of AHNAK inhibits oxidative stress and inflammatory responses by inactivating the Notch pathway. A549 cells were transfected with shNC and shAHNAK, and treated with CSE and Notch pathway agonist. (A) Cell viability was detected using CCK-8. (B) SOD activity, (C) MDA contents, and (D) LDH activity were measured using their corresponding commercialized kits. (E) TNF-α and (F) IL-6 levels were measured in the cell culture supernatant using ELISA kits. (G) ROS levels were measured using the DHE fluorescence probe. All n=3. P<0.001, P<0.01, and P<0.05 indicate statistical significance. AHNAK, AHNAK nucleoprotein; CCK-8, Cell Counting Kit-8; CSE, cigarette smoke extract; DAPI, 4’,6-diamidino-2-phenylindole; DHE, dihydroethidium; ELISA, enzyme-linked immunosorbent assay; IL, interleukin; LDH, lactate dehydrogenase; MDA, malondialdehyde; ROS, reactive oxygen species; shNC, short hairpin RNA negative control; SOD, superoxide dismutase; TNF-α, tumor necrosis factor-alpha. Discussion The present study shows that AHNAK drives COPD by promoting oxidative stress and inflammation. Mechanistically, AHNAK activates the Notch pathway to affect the cellular biological functions. To our knowledge, this is the first study to provide the function of AHNAK in the context of COPD using a loss-of-function experiments and to link its role to the Notch pathway, thereby extending previous findings that merely identified AHNAK as a DEG. Our findings establish a mechanistic link between AHNAK and key pathological processes in COPD, offering a potential therapeutic target for this refractory disease. AHNAK expression is predicted to be increased in the serum of COPD, compared with non-COPD (15). Consistent with previous study, we also found that AHNAK was highly expressed in patients with COPD than that in healthy controls. Moreover, based on the AUC value, we consider that AHNAK has significant diagnostic value for COPD, supporting the potential utility of AHNAK as a diagnostic biomarker for COPD (16). The role of AHNAK is further investigated. The pathogenesis of COPD is complex. Chronic inflammation causes airflow limitation by affecting the lung parenchyma and surrounding airways, which is closely related to the occurrence and severity of COPD (22). As a driving mechanism of inflammation, oxidative stress can promote the progression of COPD and may increase the possibility of complications (23). Therefore, clarifying the regulatory mechanisms of inflammation and oxidative stress is crucial for identifying the pathogenesis of COPD. Previous studies have demonstrated that inhibition of inflammation and oxidative stress contributes to alleviating COPD (24,25). Hence, in this study, we explored the impact of AHNAK on inflammation and oxidative stress. TNF-α and IL-6 are pro-inflammatory cytokines, and their levels increase in COPD (26). The results of our study showed that AHNAK knockdown inhibited TNF-α and IL-6 release in CSE-induced cells, suggesting that silencing of AHNAK inhibits inflammatory response, consistent with the previous research results indicating that AHNAK is closely associated with COPD-related inflammation (15). Oxidative stress is caused by excessive production and accumulation of ROS (27). SOD is an antioxidant enzyme that can combat oxidative stress, thereby protecting lipids, proteins, and nucleic acids (28). MDA is an oxidative stress marker (29). LDH activity can also reflect oxidative stress injury to a certain extent (30). In our work, the results showed that knockdown of AHNAK reduced MDA levels, LDH activity, and ROS levels, as well as increased SOD activity in CSE-induced A549 cells, suggesting that oxidative stress was suppressed by AHNAK knockdown. Moreover, in the animal study, we found that CS and LPS facilitated lung injury, oxidative stress, and inflammation, which was suppressed by AHNAK knockdown. Taken together, silencing of AHNAK alleviates the progression of COPD by suppressing inflammation and oxidative stress. We further identified that the Notch pathway was activated in CSE-induced A549 cells, and AHNAK silence inhibited the activation of this pathway. Notch pathway is a highly conserved signaling pathway and is related to the pathophysiology of various diseases (31). Notch signaling has regulatory functions in lung diseases, including COPD (32), but its role is controversial. Tilley et al. (33) found that in COPD smokers, the levels of multiple factors in the Notch pathway, such as Notch2, Hes1, and Hey1, are downregulated, indicating that this pathway is inhibited in COPD. However, Di Stefano et al. (34) have demonstrated that the Notch pathway is increased in the lungs of stable COPD patients, which damages bronchioles and lung parenchyma. Moreover, Notch has been identified to regulate inflammatory response and oxidative stress (35,36). In this study, the results showed that activation of the Notch pathway reversed the inhibition of oxidative stress and inflammation in CSE-induced cells after AHNAK knockdown, demonstrating that silencing of AHNAK alleviates COPD by inactivating the Notch pathway. Nevertheless, the role of the Notch pathway needs to be investigated in vivo in the future. COPD is a heterogeneous disease, and about 20–40% of patients present with eosinophilic airway inflammation that overlaps with severe asthma (37,38). Recognizing eosinophilic phenotypes is essential for personalized treatment plans, as they tend to respond well to corticosteroids and possibly biologics (39). Although our research found that AHNAK knockdown has an improving effect on COPD, we did not investigate its specific role in the eosinophilic subtype. Furthermore, eosinophilic inflammation is associated with alterations in mast cell characteristics in COPD (40). Emerging evidence suggests that AHNAK can also drive inflammation via immune cells, such as by activating mast cells through the ST2 pathway in psoriasis (41). However, this study only focuses on the regulatory effect of AHNAK on oxidative stress and inflammatory responses in lung epithelial cells, while it remains unknown whether it can mediate the functions of immune cells such as mast cells. Therefore, it requires further study whether AHNAK is involved in eosinophil or mast cell-mediated inflammation in COPD. This study presents several limitations. The A549 cell line, although widely used, has limitations as pulmonary alveolar type II cells and may be more suitable for the study of lung adenocarcinoma. Therefore, it would be ideal to use patient-derived primary cells. In addition, the COPD mouse models established by CS and LPS cannot fully reflect the heterogeneity of the disease, as many COPD cases occur in non-smokers (42). Future studies should test the role of the AHNAK-Notch pathway in other types of COPD models, such as eosinophilic or non-smoking-related phenotypes. Conclusions This study demonstrates that AHNAK is highly expressed in COPD and has high AUC value. It promotes COPD progression by activating the Notch signaling pathway, thereby enhancing oxidative stress and inflammatory responses. These findings suggest that AHNAK is a potential diagnostic biomarker and therapeutic target for COPD. Further studies are needed to elucidate the role of AHNAK/Notch pathway in immune cells and in distinct clinical subtypes of the disease. Supplementary The article’s supplementary files as Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-aw-2275/prf